# GOODBYE PARASITES

**HELLO SAVINGS** 

**PURCHASE A MINIMUM OF \$1,000 RECEIVE 30% REBATE ON YOUR TOTAL** 

NEW PARASEDGE<sup>™</sup> Multi | PARASEDGE<sup>™</sup> Multi for Dogs

(imidacloprid + moxidectin) **Topical Solution** 

NEW AND for Cats

(imidacloprid + moxidectin) **Topical Solution** 

**APRIL 1-JULY 31, 2022** 



# **GET THE EDGE ON PARASITES**

















**HEARTWORMS** 

**ROUNDWORMS** 

**HOOKWORMS** 

**INFESTATIONS** 

**MICROFILARIA** 

**WHIPWORMS** 

SARCOPTIC MANGE



# FRONT & CENTER APRIL 1-JULY 31, 2022

# KEEP SAVINGS PURCHASE A MINIMUM OF \$1,000 RECEIVE A 30% REBATE ON YOUR TOTAL

PRODUCT	PRODUCT#	SIZE	SUGGESTED VET PRICE
PARASEDGE™ Multi for Dogs Topical Solution - 3-9 lbs. Display	51115	10 Boxes of 3 Doses	\$298.19
PARASEDGE™ Multi for Dogs Topical Solution - 9.1-20 lbs. Display	51116	10 Boxes of 3 Doses	\$298.19
PARASEDGE™ Multi for Dogs Topical Solution - 20.1-55 lbs. Display	51117	10 Boxes of 3 Doses	\$298.19
PARASEDGE™ Multi for Dogs Topical Solution - 55.1-88 lbs. Display	51118	10 Boxes of 3 Doses	\$298.19
PARASEDGE™ Multi for Dogs Topical Solution - 88.1-110 lbs. Display	51119	5 Boxes of 3 Doses	\$149.09
PARASEDGE™ Multi for Cats Topical Solution – 2-5 lbs. Display	51120	10 Boxes of 3 Doses	\$255.00
PARASEDGE™ Multi for Cats Topical Solution - 5.1-9 lbs. Display	51121	10 Boxes of 3 Doses	\$298.00
PARASEDGE™ Multi for Cats Topical Solution – 9.1-18 lbs. Display	51122	10 Boxes of 3 Doses	\$298.00



# NEW PARASEDGE<sup>™</sup> Multi for Dogs

(imidacloprid + moxidectin) **Topical Solution** 

# NEW **PARASEDGE**<sup>™</sup> Multi **AND** for Cats

(imidacloprid + moxidectin) **Topical Solution** 

To order, contact your distributor or call your Virbac representative at 1-844-4-VIRBAC (1-844-484-7222).

Offer cannot be combined with any other Virbac offer. Eligible orders must be contained on one invoice. There is no limit to how many times a practice may participate in this offer during the offer period. Rebates will be issued in the form of a check at the end of the offer period. Offer subject to change at any time.

# Important Safety Information

PARASEDGE™ Multi for Dogs (imidacloprid + moxidectin) Topical Solution: Children should not come in contact with the application site for two (2) hours after application. Wash hands after use. Do not use this product on cats. DO NOT ADMINISTER THIS PRODUCT ORALLY. Do not use on puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight. Ensure that dogs cannot lick the product on themselves or other treated pets. Use with caution on sick, debilitated, or underweight dogs. Safety in breeding, pregnant, or lactating dogs has not been established. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

PARASEDGE™ Multi for Cats (imidacloprid + moxidectin) Topical Solution: Children should not come in contact with the application site for 30 minutes after application. Wash hands after use. DO NOT ADMINISTER THIS PRODUCT ORALLY. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not use on sick, debilitated, or underweight cats. Evaluation in geriatric cats with subclinical conditions, and safety in breeding, pregnant, or lactating cats has not been established. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

Reference 1. Data on file. Virbac Corporation.

# PARASEDGE™ Multi for Dogs (imidacloprid + moxidectin) Topical Solution

Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and pupples that are at least 7 weeks of age and that weigh at least 3 lbs.

- WARNING DO NOT ADMINISTER THIS PRODUCT ORALLY
- For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
- Children should not come in contact with application sites for two (2) hours after

e Contraindications, Warnings, Human Warnings, and Adverse Reactions, for

CAUTION:
Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

PSCRIPTION:

PARASEDGE™ Multi for Dogs (10 % imidacloprid + 2.5 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

(10 migrag) introduction and in 1 migrage 2.5 migrag introduced in date of more than the introduction of a chloronicotinn introguanidine insecticide. The chemical name for imidacloprid is 1-(6-Chloro-3-pyridinyl)methyl)-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrosyclic lactone endectocide derived from the actinomycete Syrendroveles cyaneogriseus noncyanogenus. The chemical name for moxidectin is [6R, 23E, 25S[E]-5-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbernycin B.

MOINCATONS:

PARASEDGE™ Multi for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. PARASEDGE™ Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Clenocephalides felis). PARASEDGE™ Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabier var. carris. PARASEDGE™ Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabier var. carris. PARASEDGE™ Multi for Dogs is also indicated for the treatment and control of the following intestinal parasites:

		Intestinal Stage		
Inte	Intestinal Parasite		Immature Adult	Fourth Stage Larvae
Hookworm	Ancylostoma caninum	Х	Х	Х
Species	Uncinaria stenocephala	Х	х	х
Roundworm	Toxocara canis	Х		Х
Species	Toxascaris leonina	Х		
Whipworm	Trichuris vulpis	Х		

# CONTRAINDICATIONS:

Do not administer this product orally. (See WARNINGS.)
Do not use this product (containing 2.5 % moxidectin) on cats.

# WARNINGS

VARIANIOS: For the first 30 minutes after application: Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs.

Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion

Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.

# In avermectin sensitive dogs, at the signs may be more severe and may include coma and death.

Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses. bAlthough there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care

HUMAN WARNINGS: Not for human use. Keep out of the reach of children. Children should not come in contact with application sites for two (2) hours after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache;

contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, fingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling.

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or movidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with course, take off contaminated dothing, Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

planty of sape and water Carl proson control order to impressor an eleminate average The safety data sheet (SDS) provides additional occupational sets information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Virbac AH, Inc. at 1-800-338-3659 or us virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

# PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information

Do not dispense dose applicator tubes without complete safety and administration information. Use with caution in sick, debilitated, or underweight animals. The safety of PARASEDGE™ Multi for Dogs has not been established in breeding, pregnant, or lactating dogs. The safe use of PARASEDGE™ Multi for Dogs has not been established in puppies and dogs less than 3 lbs. body weight. Prior to administration of PARASEDGE™ Multi for Dogs, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of PARASEDGE™ Multi for Dogs has not been evaluated when administered on the same day as an adulticide. PARASEDGE™ Multi for Dogs, is not effective against adult D. mrimits. Although the number of circulating microfiliariae is substantially reduced in most dogs following treatment with PARASEDGE™ Multi for Dogs, the microfiliariae ount in some heartwormpositive dogs may increase or remain unchanged following treatment with PARASEDGE™ Multi for Dogs, does not en expert with melarsomine dihyrocholicus (See ADVERSE REACTIONS and ANIMAL SAFETY - Safety Study in Heartworm-Positive Dogs.)

PARASEDGE™ Multi for Dogs has not been evaluated in heartworm-positive dogs with

PARASEDGE™ Multi for Dogs has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease

# ADVERSE REACTIONS:

# Heartworm-Negative Dogs

Field Studies: Following treatment with imidacloprid and moxidectin topical solution or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION	imidacloprid and moxidectin topical solution n=128	Active Control n=68
Pruritus	19 dogs (14.8 %)	7 dogs (10.3 %)
Residue	9 dogs (7.0 %)	5 dogs (7.4 %)
Medicinal Odor	5 dogs (3.9 %)	None observed
Lethargy	1 dog (0.8 %)	1 dog (1.5 %)
Inappetence	1 dog (0.8 %)	1 dog (1.5 %)
Hyperactivity	1 dog (0.8 %)	None observed

During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized prunitus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, imidacloprid and moxidectin topical solution was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with finidaclopid and moxidectin topical solution included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma.

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsfeadiness between 6 and 9 days after application with imidacloprid and moxidectin logical solution. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of imidacloprid and moxidectin topical solution.

days after application or influedcoping and influedcettin topical solution. The following clinical observations also occurred in laboratory effectiveness studies following application with imidacloprid and moxidectin topical solution and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

# Heartworm-Positive Dogs

Heartworm-Positive Dogs
Field Study: A 56-day field safely study was conducted in 214 D. immitis heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received imidacloprid and moxidectin topical solution on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days -14, 14 and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating D. Immitis microfilariae was > 90 % at the of six sixels; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with mindacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride.

Following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed:

Adverse Reaction	Dogs Treated with imidacloprid and moxidectin topical solution Only n=106	Dogs Treated with imidacloprid and moxidectin topical solution + Melarsomine n=108
Cough	24 (22.6 %)	25 (23.1 %)
Lethargy	14 (13.2 %)	42 (38.9 %)
Vomiting	11 (10.4 %)	18 (16.7 %)
Diarrhea, including hemorrhagic	10 (9.4 %)	22 (20.4 %)
Inappetence	7 (6.6 %)	19 (17.6 %)
Dyspnea	6 (5.7 %)	10 (9.3 %)
Tachypnea	1 (< 1 %)	7 (6.5 %)
Pulmonary Hemorrhage	0	1 (< 1 %)
Death	0	3 (2.8 %)

Three dogs treated with imidacloprid and moxidectin topical solution in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with imidacloprid and moxidectin topical solution and solution and solutions and solutions are solved in the solution of nearworms. One door, related with minactorphic and introduction procurs solution and melarsomine dihydrochloride, experienced pullmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with imidacloprid and moxidectin topical solution alone, two dogs experienced adverse reactions (coupling, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to imidacloprid and moxidectin topical solution following the first treatment than the second treatment.

To report a suspected adverse reaction, call 1-800-338-3659.

# Post-Approval Experience

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in dogs are listed in decreasing order of reporting frequency depression/lethary, vomiting, pruits, diarrhea, anorexia, hyperactivity, ataxia, trembling, hypersalivation, application site reactions (alopecia, pruritus, lesions, and erythema), seizures, and anaphylaxis/anaphylactic reactions (hives, urticaria, facial swelling, edema of the head).

# Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product.

In humans, nausea, numbness or tingling of the mouthlips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product.

To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.


1. Use scissors to open the foil pack, taking care not to damage the tube inside. Remove one dose applicator tube from the package and hold the tube in an upright position. As specified in the following table, administer the entire contents of the PARASEDGE\* Multi for Dogs (imidacloprid + moxidectin) tube that correctly corresponds with the body weight of the dog.

Dog (lbs.)	PARASEDGE™ Multi for Dogs	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
3 - 9	PARASEDGE™ Multi 9	0.4	40	10
9.1 - 20	PARASEDGE™ Multi 20	1.0	100	25
20.1 - 55	PARASEDGE™ Multi 55	2.5	250	62.5
55.1 - 88	PARASEDGE™ Multi 88	4.0	400	100
88.1 - 110*	PARASEDGE™ Multi 110	5.0	500	125

\*Dogs over 110 lbs. should be treated with the appropriate combination of PARASEDGE™ Multi for Dogs tubes.

2. Bend the tip back until it snaps off. If it doesn't snap off at first, cut it using scissors.

3. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and may the out.





tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.

4. Keep tube compressed on the final squeeze to avoid drawing liquid back into tube. While keeping tube squeezed, drag it away from liquid and lift up to remove.

Do not let this product get in your dog's mouth or eyes. **Do not allow the dog to lick any of the application sites for 30 minutes**. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (**See WARNINGS**.)

Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Dogs should be administered at one-month intervals PARASEDGE™ Multi for Dogs may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 31-day interval between doses is exceeded, administer PARASEDGE™ Multi for Dogs immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Dogs should be given within one month of the last dose of the former medication.

Treatment of Circulatina Microfilaria: For the treatment of circulatina D, immitis microfilaria.

Treatment of Circulating Microfilaria: For the treatment of circulating D. immitis microfilaria in heartworm-positive dogs, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because PARASEDGE™ Multi for Dogs is not effective for the treatment of adult D. immitis. (See PRECAUTIONS.)

Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of PARASEDGE™ Multi for Dogs is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of pre-existing puppe in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidaclopind, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog.

# Treatment and Control of Intestinal Nematode Infections:

For the treatment and control of intestinal hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala (adults, immature adults and fourth stage larvae) and roundworm infections caused by l'oxocara canis (adults and fourth stage larvae), and roundworm infections caused by l'oxocara canis (adults and fourth stage larvae), and produce the control of the c

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis, PARASEDGE™ Multi for Dogs should be administered as a single topical dose. A second monthly dose may be administered if necessary.

# ANIMAL SAFETY:

# Heartworm-Negative Dogs

Heartworm-Negative Dogs
Fleid Study: In a controlled, double-masked, field safety study, imidacloprid and moxidectin topical solution was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. Imidacloprid and moxidectin topical solution was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antimistamines, antimicrobials, chondroprotectants, conticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of imidaclopid and moxidectin topical solution; purufus, flakylgreasy residue at the treatment site, medicinal odor, lethargy, inappetence, and hyperactivity. (See ADVERSE REACTIONS.) residue at the treatment site, me (See ADVERSE REACTIONS.)

(See ADVERSE REACTIONS.)

Safety Study in Puppies: Imidacloprid and moxidectin topical solution was applied topically at 1, 3 and 5X the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 55 and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1X treatment group (day 57), in two puppies from the 3X treatment group (days 1 and 79), and in one puppy from the 5X treatment group (day 1). Two puppies each in the 1X, 3X, and 5X groups had decreased appetites within 24 hours post-dosing. One puppy in the 1X treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5X treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: Imidacloprid and moxidectin topical solution was administered topically to 8-month-old Beagle dogs at 10X the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

ureased group on not gain as much weight as the control group.

Oral Safety Study in Beagles: Imidacloprid and moxidectin topical solution was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle temors, and dilated pulps with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing. (See CONTRAINDICATIONS.)

Dermal Safety Study in Ivermectin-Sensitive Collies: Imidacloprid and moxidectin topical solution was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been p screened for avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies: Imidacloprid and moxidectin topical solution was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10 % of the minimum labeled dose. At 40 % of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were euthanized. (See CONTRAINDICATIONS.)

# Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: Imidacloprid and moxidectin topical solution was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

STORAGE INFORMATION: Store below 25°C (77°F).

**HOW SUPPLIED:** Applications Per Package:  $3 \times 0.4$  mL tubes,  $3 \times 1.0$  mL tubes,  $3 \times 2.5$  mL tubes,  $3 \times 4.0$  mL tubes,  $3 \times 5.0$  mL tubes

Approved by FDA under ANADA # 200-700 PARASEDGE™ is a trademark of Virbac S.A. © 2021 Virbac Corporation. All Rights Reserved Manufactured for: Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 I A20679 Rev 10/2021



# PARASEDGE™ Multi for Cats (imidacloprid + moxidectin) Topical Solution

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that weigh at least 2 lbs.

# CAUTION:

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian.

# DESCRIPTION:

DESCRIPTION:
PARASEDGE™ Multi for Cats (10% imidacloprid + 1% moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of cats. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin based on body weight

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name of imidacloprid is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete Streptomycetes cyaneogriseus noncyanogenus. The chemical name of moxidectin is [6R, 23E, 255(E)]-S-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:

PARASEDGE™ Multi for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. PARASEDGE™ Multi for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. PARASEDGE™ Multi for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following intestinal parasites:

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	Ancylostoma tubaeforme	Х	Х	Х
Roundworm Species	Toxocara cati	Х		Х

# WARNINGS:

Do not use on sick, debilitated, or underweight cats (See ADVERSE REACTIONS).

Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.

## HUMAN WARNINGS:

Not for human use. Keep out of the reach of children. Children should not come in contact with the application site for 30 minutes after application.

Causes eve irritation. Harmful if swallowed. Do not get in eyes or on Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician inmediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce the product of the p Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides more detailed occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact VIRBAC AH, Inc. at 1-800-338-3659 or usvirbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

# PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information

Avoid oral ingestion. Cats may experience hypersalivation, tremors, vomiting and decreased appetite if PARASEDGE™ Multi for Cats is inadvertently administered orally or through grooming/licking of the application site

The safety of PARASEDGE™ Multi for Cats has not been established in breeding, pregnant, or lactating cats.

The effectiveness of PARASEDGE™ Multi for Cats against heartworm infections (D. immitis) after bathing has not been evaluated in cats.

Use of this product in geriatric patients with subclinical conditions has not been adequately studied. Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug. (See ADVERSE REACTIONS.)

# ADVERSE REACTIONS

Field Study: Following treatment with imidacloprid and moxidectin or an active control, cat owners reported the following post-treatment reactions:

OBSERVATION	Imidacloprid and moxidectin n=113	Active Control n=38
Lethargy (protracted sleeping, poorly responsive)	3 cats* (2.7 %)	None observed
Behavioral changes (e.g., agitated, excessive grooming, hiding, pacing, spinning)	9 cats (8.0 %)	1 cat (2.6%)
Discomfort (e.g., scratching, rubbing, head shaking)	5 cats (4.4 %)	None observed
Hypersalivation (within 1 hour after treatment)	3 cats (2.7 %)	None observed
Polydipsia	3 cats (2.7 %)	None observed
Coughing and gagging	1 cat (0.9 %)	None observed

<sup>\*</sup>These three cats were from the same household and included one 13-yr-old cat in good health, one 15-yr-old FIV positive cat in good

health, and one 15-yr-old, underweight cat in fair health. Lethargy was noted for 24 to 36 hrs after the first treatment only; one cat was unsteady at 48 hrs. These cats were not on other medications.

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS.)

Laboratory Effectiveness Studies: Imidacloprid and moxidectin was administered at the recommended dose to 215 cats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the cause of death. A second cat that became ill 3 days after application of imidacloprid and moxidectin responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and lesions attributable to panleukopenia on day 7 after moxidectin application.

Post-approval Experience: The following adverse events are based on post approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/lethargy, application site reactions (alopecia, pruritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding)

In some cases death has been reported.

In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to this product. To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www. fda.gov/reportanimalae

# DOSAGE AND ADMINISTRATION:

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

As specified in the following table, administer the entire contents of the PARASEDGE™ Multi for Cass (10% imidacloprid + 1% moxidectin) tube that correctly corresponds with the body weight of the cat.

Cat (lb.)	PARASEDGE™ MULTI For Cats	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
2-5	PARASEDGE™ MULTI 5	0.23	23	2.3
5.1-9	PARASEDGE™ MULTI 9	0.4	40	4
9.1-18*	PARASEDGE™ MULTI 18	0.8	80	8

\*Cats over 18 lbs. should be treated with the appropriate combination of PARASEDGE™ Multi for Cats tubes.



1. Use scissors to open the foil pack, taking care not to damage the tube inside. Remove the tube from the foil pack and hold upright with the lot and expiration at the bottom 2. Bend the tip back until it snaps off. If it doesn't snap off at first, cut it using scissors.



3. Part the hair on the back of the cat's neck at the base of the neck, in front of the shoulder blades, until the skin is visible.

**4.**Place the tip of the PARASEDGE™ Multi for Cats tube on the skin. Squeeze the tube firmly 3-4 times in one spot until empty. Keep tube compressed on the final squeeze to avoid drawing liquid back into the tube. Avoid contact between PARASEDGE™ Multi for Cats and your fingers.



**5.** While keeping tube squeezed, drag it away from liquid and lift up to remove.

6. Ensure tube is empty.

Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.

Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Cats should be administered at one-month intervals. PARASEDGE™ Multi for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE™ Multi for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats older than 6 months of age may be tested to determine the presence of existing heartworm infection before treatment with PARASEDGE™ Multi for Cats (See ADVERSE REACTIONS Post-Approval Experience).

Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of PARASEDGE™ Multi for Cats is administered, adult fleas on the cat will be killed. However, re-infestation from the emergence of pre-existing pupae

in the environment may continue to occur for six weeks or longer after treatment is initiated. Cats treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the cat.

Ear Mite Treatment: For the treatment of ear mites (Otodectes cynotis), PARASEDGE™ Multi for Cats should be administered once as a single topical dose. Monthly use of PARASEDGE™ Multi for Cats will control any subsequent ear mite infestations.

Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara cati* (adults and fourth stage larvae), PARASEDGE™ Multi for Cats should be administered once as a single topical dose.

## ANIMAL SAFETY:

Studies in Kittens: Imidacloprid and moxidectin was topically applied at 0, 1, 3, and 5X the maximum dose to 48 healthy 9-week-old kittens on days 0, 28, and 56. Lethargy was observed in 1 kitten from the 3X group ody's 0, 28, allo 36. Eethalgy was observed in Fixtuer I norm the 3X group on the day after initial treatment; the Kitten from the 3X group was also disoriented and ataxic. One kitten from the 3X group had a slow pupillary light response two days after treatment and one had tremors the day after treatment. Hypersalivation was seen in one kitten from the 5X group approximately six hours post-treatment. in one kitten from the SX group approximately six hours post-treatment. One kitten from the 3X group was scratching at the treatment site 2 days after treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Histopathology showed granulomatous inflammation at the treatment site in three 1X kittens. Causal relationship to the drug could not be determined. Pulmonary inflammation (1-SX) and lymphoid hyperplasia (2-1X, 4-3X) were seen in treated kittens. In a second study, imidacloprid and moxidectin was topically applied at 0, 1.7, 5.2 and 8.7X the maximum dose to 48 healthy 9-week-old kittens every two weeks for 6 doses. One kitten in the 8.7X group apparently ingested an unknown amount of the drug and developed the following clinical signs prior to amount of the drug and developed the following clinical signs prior to euthanasia: mydriasis, salivation, depression, vomiting, unsteadiness, rapid to slow to difficult breathing, poor pupillary response, generalized tremors, inability to move, and nystagmus. Two kittens in the 5.2X group developed mydriasis, salivation, depression, squinting, and poor appetite. A kitten in the 1.7X group developed mydriasis.

Dose Tolerance Study: Eight healthy juvenile cats were topically dosed with a single application of imidicloprid and moxidectin at 10 times the recommended dose volume. Mild, transient hypersalivation occurred in two of the cats.

Oral Study in Cats: The oral safety of imidacloprid and moxidectin was tested in case of accidental oral ingestion. The maximum topical dose was orally administered to twelve healthy 9-week-old kittens. Hypersalivation (8 of 12 kittens) and vomiting (12 of 12 kittens) were observed immediately post-treatment. Tremors developed in one kitten within 1 hour, resolving without treatment within the next hour. All 12 kittens were either anorexic or had decreased appetite for at least 1 day following treatment. In 3 kittens, the anorexia or decreased appetite continued into the second week following treatment. There was a continued into the section were following learning. There was a post-treatment loss of body weight in treated kittens compared to control kittens. In a pilot safety study using kittens younger in age and lighter in weight than allowed by product labeling, an 8-week old kitten weighing 0.6 kg orally received 2X of the label topical dose (0.46 m.L/kg). Immediately after dosing, it womited, had labored breathing and slight tremors. Within 4 hours, it was normal, but was found dead on day 6. Necropsy could not determine the cause of death.

Study in Heartworm Positive Cats: Young adult cats were inoculated Study in Heartworm Positive Cats: Young adult cats were inoculated subcutaneously with third-stage *D. Immitis* larvae. At 243-245 days post-infection, immunoserology and echocardiography were performed to identify cats with adult heartworm burdens similar to naturally-acquired infections. Two groups were treated topically with either imidacloprid and moxidectin at the label dose or placebo, once every 28 days, for three consecutive treatments. A third group was treated topically, once, with imidacloprid and moxidectin at St the label dose. Sporadic vomition and labored hearthing related to heartworm dose. Sporadic vomiting and labored breathing related to heartworm burden were observed in the treatment and control groups. There was no difference between treatment groups in the numbers of adult D. immitis recovered at study conclusion. No adverse reactions were associated with the topical application of imidacloprid and moxidectin to experimentally heartworm-infected cats.

STORAGE INFORMATION: Store below 25°C (77°F

HOW SUPPLIED: Applications Per Package 3 x 0.23 mL tubes 3 x 0.4 ml tubes 3 x 0.8 mL tubes

Approved by FDA under ANADA # 200-701

PARASEDGE™ is a trademark of Virbac AH, Inc. © 2020 Virbac Corporation. All Rights Reserved.

Manufactured for: Virbac AH, Inc. P.O. Box 162059, Fort Worth, TX 76161

01 - 09/21 LA20219

